Anti-angiogenic effects and mechanism of prazosin

Prostate

Volumn 71, Issue 9, 2011, Pages 976-984

  Liao, Chun Hou ^a   Guh, Jih Hwa ^b   Chueh, Shih Chieh ^c,d   Yu, Hong Jeng ^c  

^a FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

alpha adrenoceptor antagonist; angiogenesis; apoptosis; prazosin

Indexed keywords

CYTOCHROME C; DOXAZOSIN; PRAZOSIN; PROTEIN BAD; PROTEIN BCL XL; PROTEIN MCL 1; RHODAMINE 123; TAMSULOSIN; TERAZOSIN;

ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE PROGRESSION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIUM CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC 50; MITOCHONDRIAL MEMBRANE; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; ANGIOGENESIS INHIBITORS; APOPTOSIS; BLOTTING, WESTERN; CELL SURVIVAL; ENDOTHELIAL CELLS; FLOW CYTOMETRY; HUMANS; MALE; MEMBRANE POTENTIAL, MITOCHONDRIAL; NEOVASCULARIZATION, PATHOLOGIC; PRAZOSIN; PROSTATIC HYPERPLASIA;

EID: 79955575350     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21313     Document Type: Article

References (24)

1. Hansson L, Himmelmann A,. Carvedilol in the treatment of hypertensiona-A review of the clinical data base. Scand Cardiovasc J Suppl 1998; 47: 67-80.
2. Pool JL, Kirby RS,. Clinical significance of alpha1-adrenoceptor selectivity in the management of benign prostatic hyperplasia. Int Urol Nephrol 2001; 33: 407-412.
3. Siddiqui EJ, Shabbir M, Thompson CS, Mumtaz FH, Mikhailidis DP,. Growth inhibitory effect of doxazosin on prostate and bladder cancer cells. Is the serotonin receptor pathway involved? Anticancer Res 2005; 25: 4281-4286. (Pubitemid 41665217)
4. Ito K, Ohtani H, Sawada Y,. Assessment of alpha1-adrenoceptor antagonists in benign prostatic hyperplasia based on the receptor occupancy theory. Br J Clin Pharmacol 2007; 63: 394-403. (Pubitemid 46426632)
5. Harris AM, Warner BW, Wilson JM, Becker A, Rowland RG, Conner W, Lane M, Kimbler K, Durbin EB, Baron AT, Kyprianou N,. Effect of alpha1-adrenoceptor antagonist exposure on prostate cancer incidence: An observational cohort study. J Urol 2007; 178: 2176-2180. (Pubitemid 47538576)
6. Dean EJ, Ranson M, Blackhall F, Holt SV, Dive C,. Novel therapeutic targets in lung cancer: Inhibitor of apoptosis proteins from laboratory to clinic. Cancer Treat Rev 2007; 33: 203-212. (Pubitemid 46323397)
7. Kyprianou N, Benning CM,. Suppression of human prostate cancer cell growth by alpha1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis. Cancer Res 2000; 60: 4550-4555. (Pubitemid 32103639)
8. Tahmatzopoulos A, Rowland RG, Kyprianou N,. The role of alpha-blockers in the management of prostate cancer. Expert Opin Pharmacother 2004; 5: 1279-1285. (Pubitemid 38885789)
9. Hui H, Fernando MA, Heaney AP,. The alpha1-adrenergic receptor antagonist doxazosin inhibits EGFR and NF-kappaB signalling to induce breast cancer cell apoptosis. Eur J Cancer 2008; 44: 160-166. (Pubitemid 350256942)
10. Keledjian K, Kyprianou N,. Anoikis induction by quinazoline based alpha 1-adrenoceptor antagonists in prostate cancer cells: Antagonistic effect of bcl-2. J Urol 2003; 169: 1150-1156. (Pubitemid 36188191)
11. Pan SL, Guh JH, Huang YW, Chern JW, Chou JY, Teng CM,. Identification of apoptotic and antiangiogenic activities of terazosin in human prostate cancer and endothelial cells. J Urol 2003; 169: 724-729.
12. Keledjian K, Garrison JB, Kyprianou N,. Doxazosin inhibits human vascular endothelial cell adhesion, migration, and invasion. J Cell Biochem 2005; 94: 374-388. (Pubitemid 41420315)
13. Hu ZW, Shi XY, Hoffman BB,. Doxazosin inhibits proliferation and migration of human vascular smooth-muscle cells independent of alpha1-adrenergic receptor antagonism. J Cardiovasc Pharmacol 1998; 31: 833-839. (Pubitemid 28265292)
14. Keledjian K, Borkowski A, Kim G, Isaacs JT, Jacobs SC, Kyprianou N,. Reduction of human prostate tumor vascularity by the alpha1-adrenoceptor antagonist terazosin. Prostate 2001; 48: 71-78. (Pubitemid 32613870)
15. Kintscher U, Kon D, Wakino S, Goetze S, Graf K, Fleck E, Hsueh WA, Law RE,. Doxazosin inhibits monocyte chemotactic protein 1-directed migration of human monocytes. J Cardiovasc Pharmacol 2001; 37: 532-539. (Pubitemid 32377909)
16. Lin SC, Chueh SC, Hsiao CJ, Li TK, Chen TH, Liao CH, Lyu PC, Guh JH,. Prazosin displays anticancer activity against human prostate cancers: Targeting DNA and cell cycle. Neoplasia 2007; 9: 830-839.
17. Tahmatzopoulos A, Kyprianou N,. Apoptotic impact of alpha1-blockers on prostate cancer growth: A myth or an inviting reality? Prostate 2004; 59: 91-100. (Pubitemid 38387846)
18. Fernando MA, Heaney AP,. Alpha1-adrenergic receptor antagonists: Novel therapy for pituitary adenomas. Mol Endocrinol 2005; 19: 3085-3096. (Pubitemid 41697723)
19. Kintscher U, Wakino S, Kim S, Jackson SM, Fleck E, Hsueh WA, Law RE,. Doxazosin inhibits retinoblastoma protein phosphorylation and G(1)âS transition in human coronary smooth muscle cells. Arterioscler Thromb Vasc Biol 2000; 20: 1216-1224. (Pubitemid 30262921)
20. Austin PF, Cook BL, Niederhoff RA, Manson SR, Coplen DE, Weintraub SJ,. Inhibition of mitogenic signaling and induction of apoptosis in human bladder smooth muscle cells treated with doxazosin. J Urol 2004; 172: 1662-1665.
21. Garrison JB, Shaw YJ, Chen CS, Kyprianou N,. Novel quinazoline-based compounds impair prostate tumorigenesis by targeting tumor vascularity. Cancer Res 2007; 67: 11344-11352. (Pubitemid 350248561)
22. Ciccarelli M, Santulli G, Campanile A, Galasso G, CervÃ?ro P, Altobelli GG, Cimini V, Pastore L, Piscione F, Trimarco B, Iaccarino G,. Endothelial alpha1-adrenoceptors regulate neo-angiogenesis. Br J Pharmacol 2008; 153: 936-946.
23. Garrison JB, Kyprianou N,. Doxazosin induces apoptosis of benign and malignant prostate cells via a death receptor-mediated pathway. Cancer Res 2006; 66: 464-472. (Pubitemid 43166055)
24. Antonello A, Hrelia P, Leonardi A, Marucci G, Rosini M, Tarozzi A, Tumiatti V, Melchiorre C,. Design, synthesis, and biological evaluation of prazosin-related derivatives as multipotent compounds. J Med Chem 2005; 48: 28-31. (Pubitemid 40105246)